EpistemisSynthesis: Integrated Antimicrobial Clinical Pathway
The empirical selection of an antimicrobial and its subsequent analytical optimization is one of the most critical tasks in emergency clinical practice and intensive care medicine. The following table summarizes the targets, PK/PD profiles, toxicities and settings of the main therapeutic families.
Mechanism
| Reference Drug | Critical Molecular Target | Cardinal PK/PD Parameter | Cardinal Course Toxicity | Precision Adjustment in Kidney Failure |
|---|---|---|---|---|
| Penicillin G | PBP1 / PBP3 (Wall) | %T > MIC | Neurotoxicity / Seizures | Reduce if Clcr < 30 mL/min |
| Amoxicillin + Clavulanic | PBPs + Serine Inhibitor | %T > MIC | Gastric diarrhea / Cholestatic hepatitis | Reduce if Clcr < 30 mL/min |
| Piperacillin + Tazobactam | Pseudomonas PBP3 | %T > MIC | Transient platelet dysfunction | Reduce if Clcr < 40 mL/min |
| Cefazolin | PBP1 / PBP3 (Gram-positive) | %T > MIC | Immunoallergic rash | Reduce if Clcr < 35 mL/min |
| Ceftriaxone | PBP2 / PBP3 (Gram-negative) | %T > MIC | Cholestatic biliary sludge / Kernicterus | No routine dose adjustment required |
| Cefepime | Zwitterion - dural porins | %T > MIC | Encephalopathy / Non-convulsive state | Reduce if Clcr < 50 mL/min |
| Cefiderocol | Siderophore (Iron TonB) | %T > MIC | Mild cortical seizures | Reduce if Clcr < 60 mL/min |
| Meropenem | Broad-spectrum PBP2 / PBP3 | %T > MIC | Mild transient thrombocytopenia | Reduce if Clcr < 50 mL/min |
| Ertapenem | Carbapenem without Pseudomonas | %T > MIC | Local disorders in IM injection | Reduce if Clcr < 30 mL/min |
| Aztreonam | Strict Gram-negative PBP3 | %T > MIC | Elevated liver enzymes | Reduce if Clcr < 30 mL/min |
| Vancomycin | ||||
| Amikacin | 30S ribosomal subunit binding | fCmax/MIC | Ototoxicity / Renal tubular failure | Adjust once daily dose interval |
| Azithromycin | 50S ribosomal subunit binding | fAUC24/CIM | QTe Interval Prolongation | No routine dose adjustment required |
| Clindamycin | 50S antitoxin inhibitor | fAUC24/CIM | Colitis due to C. difficileaqueous | Does not require routine dose adjustment |
| Doxycycline | Reversible binding 30S subunit | fAUC24/CIM | Stains in dental bone enamel | Does not require routine dose adjustment |
| Tigecycline | Large volume 30S subunit | fAUC24/CIM | Recurrent severe nausea | Adjust only in Child-Pugh C cirrhosis |
| Linezolid | 70S initiator complex blockade | fAUC24/CIM | Myelosuppression / Serotonin syndrome | No routine dose adjustment required |
| Daptomycin | Calcium membrane aggregate | fCmax/MIC | Proximal myopathy / rhabdomyolysis | Space every 48 hours if Clcr < 30 |
| Colistin | Lipid A cationic detergent | fAUC24/MIC | Severe proximal tubular nephrotoxicity | Reduce daily maintenance dose |
| Ciprofloxacin | DNA Gyrase (Gram-negative) | fAUC24/CIM | Achilles tendinitis / Arterial rupture | Reduce if Clcr < 50 mL/min |
| Cotrimoxazole | Double enzyme blockade DHPS+DHFR | fAUC24/CIM | Stevens-Johnson / Hyperkalemia | Reduce if Clcr < 30 mL/min |
| Metronidazole | Anaerobic DNA free radicals | fCmax/CIM | Painful neuropathy / Antabuse Effect | Reduce only in Child-Pugh C cirrhosis |
| Nitrofurantoin | Mixed bacterial genomic destruction | fAUC24/CIM | Chronic irreversible pulmonary fibrosis | Contraindicated if Clcr < 30 mL/min |
| Voriconazole | Lanosterol 14-alpha-demethylase | fAUC24/CIM | Transient visual disturbances | Avoid IV route if Clcr < 50 mL/min |
| Anidulafungin | Fungal 1,3-beta-D-glucan synthase | fAUC24/CIM | Transient flushing in infusion | Does not require urinary dose adjustment |
Clinical
Rapid Decision Clinical Algorithm for Septic Shock
When faced with a patient in septic shock of unknown origin in the emergency unit, an empirical regimen should be prescribed that optimizes the biological variables:
- Immediate collection of blood cultures: At least two culture bottles (aerobic and anaerobic) before starting the dose, without delaying the infusion for more than 45 minutes.
- Initiating Broad Spectrum Regimen: Piperacillin-Tazobactam (4.5 g IV) or Meropenem (2 g IV) administered immediately as a bolus or rapid infusion to reach the target plasma peak, supplemented with Vancomycin (loading dose of 25-30 mg/kg) if there is a proven clinical suspicion of MRSA.
- Adjustment and De-escalation after 48-72 hours: Direct the antibiotic specifically based on the antibiogram, reducing the spectrum to preserve the patient's native microbiota.
"The inappropriate use of an antibiotic in the present not only harms the patient who receives it, but also destroys the therapeutic future of the entire community." — Fundamental Clinical Axiom of Infectology.
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Antimicrobial and Infectious
- Cluster
- Atlas of Pharmacoselection and Precision Decisions